Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

esults we announced last week for the 111 study. Both these ABPM trials suggest that naproxcinod's 24-hour blood pressure profile is improved compared to naproxen's and we are eager to receive the results of the ongoing 112 ABPM study in the coming months."

The 104 trial was an 8-week, double-blind, randomized, cross-over study, in which 131 hypertensive volunteers between 50 and 75 years of age were enrolled to receive either naproxcinod 750 mg bid for 2 weeks, followed by naproxen 500 mg bid for 2 weeks, or these compounds in the reverse order. Subjects received a 2-week placebo wash-out at the beginning of the study and between the active treatment periods. Eligible subjects were not current Non-Steroidal Anti-Inflammatory Drug (NSAID) users, had controlled hypertension, and could receive stable doses of up to 2 different classes of antihypertensive drugs.

NicOx is developing naproxcinod in late phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to traditional NSAIDs and COX-2 inhibitors. The results of the third phase 3 trial for naproxcinod (the 303 study) are expected before the end of the year and the filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting N
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Gain recognition for leadership and contribution ... biotech industry. Nominations are now being accepted for ... by the Bio Supply Management Alliance , ... professionals for the past 7 years. , Awards ... industry – Manufacturers, Service Providers, Material Suppliers, Technology ...
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
(Date:7/24/2014)... July 24, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... Potassium Sulphate basic information, including its definition, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... ARBOR, Mich., Oct. 24 Gene Codes ... immediate,availability of the next version of Sequencher, ... analysis program. Researchers in academic labs ... which contains the essential genetic instructions key ...
... (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will ... the Financial,Services Exchange (FSX) Investment Conference at the ... October 25, 2007. Immunosyn has obtained exclusive ... its largest shareholder, Argyll,Biotechnologies, LLC. Research suggests that ...
... Environment Where Scientists Thrive and Science is ... ... year, Abbott (NYSE: ABT ) has been named among the top ... Science is at the center of Abbott,s broad base of businesses. To,enhance ...
Cached Biology Technology:Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis 2Immunosyn Corporation to Present at FSX 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... biomedical engineering at the University of Houston, has ... artificial organ development., "Introduction to Tissue Engineering: Applications ... into the field of artificial organ development. Metin ... at UH, served as a series editor on ... other published books on the subject of growing ...
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... Omnicell, Inc . (NASDAQ: OMCL ), a ... analytics software for healthcare facilities, today announced that ... supply and medication management solutions with the new fourth ... decade as an Omnicell pharmacy and supply automation customer, ...
... The cerebellum is far more intensively involved in helping ... effectively in spatial environments our brain, and particularly our ... cerebellum contributes to the creation of this map through ... ability is inactivated, the brain is no longer able ...
... available in Chinese on EurekAlert! Chinese . ... have published new research that improves the survival and effectiveness ... Chang Chan, from the Chinese University of Hong Kong, is ... has led to a variety of breakthroughs as stem cell ...
Cached Biology News:Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 2Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 3Athens Regional Medical Center Upgrades to Omnicell G4 Platform for Supply and Medication Management 4The cerebellum as navigation assistant 2Reprogramming stem cells to a more basic form results in more effective transplant, study shows 2
... Reagent A - Fixation medium Reagent ... are intended for fixing cells in suspension ... cells with Reagent B. This procedure gives ... the morphological scatter characteristics of the cells ...
... Intended Use: Vision Mount is formulated for covering ... alcohol soluble OR alcohol insoluble end products. , ... ... with chromogens such as Fast-Red or AEC that require an ...
... Solution, High pH This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: